Timely and Accurate Diagnosis of Monogenic Diabetes Is Crucial
Monogenic diabetes is a type of diabetes caused by a change in a single gene and includes neonatal diabetes, maturity-onset diabetes of the young (MODY) and syndromic forms of diabetes. Timely and accurate diagnosis is crucial because it guides screening, treatment and cascade testing of family members. A confirmed genetic diagnosis can spare patients unnecessary or less effective therapy, flag related health issues that need monitoring and help identify relatives who may benefit from evaluation. Because monogenic diabetes can share some features with type 1 and type 2 diabetes, it can sometimes be hard to tell them apart.
When to Consider Referral for Monogenic Diabetes
Genetic testing is strongly recommended for children diagnosed with diabetes before 6 months of age. For other children and young adults, consider referral for specialized evaluation when they present with:
- Atypical diabetes presentations, including lower-than-expected insulin requirements.
- Negative islet autoantibodies and clinical features inconsistent with type 2 diabetes, such as the absence of insulin resistance or elevated BMI.
- Diabetes with other organ system findings, including sensorineural hearing loss or renal cysts.
- Diabetes across successive generations, suggesting a possible inherited form.
Negative islet autoantibodies alone do not rule out type 1 diabetes and should be interpreted alongside other clinical findings.
“Getting the right diagnosis enables us to offer more targeted treatment options. Depending on the type of monogenic diabetes, some patients who were told they need insulin injections may do well on a pill or a GLP-1 receptor agonist instead, and some may not even need medication at all,” says Lily Deng, MD, a pediatric endocrinologist at Cincinnati Children’s Division of Diabetes and Endocrinology.
Genetic Diagnosis Guides Targeted Treatment
Maturity-onset diabetes of the young (MODY) is a form of monogenic diabetes. Management for MODY is specific to the genetic subtype. For example, GCK-MODY causes mild hyperglycemia that typically does not require medication, whereas HNF1A-MODY or HNF4A-MODY can be treated with sulfonylureas. Recent research also shows promising potential for treating HNF1A-MODY and HNF4A-MODY with GLP-1-based therapies.
Because common forms of MODY can be autosomal dominant, a confirmed variant can also prompt evaluation of close relatives with diabetes and help optimize their care.



